Decent beat in Q3 Sales- FY guidance lifted.

Novartis acquires a US-based neuroscience company for $12bn.

Strong beat at Operating level notably thanks to Dupixent.

Q3 sales mark an improvement in momentum.

Strong performance in Q3 and FY guidance (only) confirmed.

Successsful listing of TKMS is encouraging.